Our team is also on hand to answer any questions
Semaglutide (STEP trials) In the landmark STEP 1 trial, participants on semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% for placebo
While compounded medications are not FDA-approved, they are often used when branded medications are in short supply or when a patient requires a specific dosage or formulation not available commercially
Those are pharmacology results, not proof of a clinical benefit there is no controlled human trial showing CJC-1295 improves body composition, a disease outcome, or any functional measure, and the no-DAC form has no controlled human trials at all
Now, the real-world use is broader, messierand more revealing
Oestrogen production falls sharply, while androgen levels decline less, creating relative androgenicity and an adverse cardiometabolic profile [134]